Additional Relevant Details "The launch of HETLIOZ in Germany reflects our continued focus to bring a treatment option to Non-24 patients across the globe," said Gian Piero Reverberi, Vanda's Senior Vice President and Chief Commercial Officer. "We are very pleased with our first HETLIOZ launch outside of the United Statesand look forward to making HETLIOZ available in additional countries in the coming years."